The co-founder and CEO of LeagueSide talks about how his company is helping to strengthen youth sports communities in a creative way.

2. We heard the Learned Counsel for the parties. This application was filed by the Applicant in the matter of the grant of the mining lease to the Respondent No.1 for executing the construction work of the road from the Jaora-Piplodha-Jalandharkheda & Piploda - Sailana at the instance of the Respondent No. 8/Madhya Pradesh Road Development Corporation Ltd. (MPRDC). For the aforesaid purpose the Respondent No.1 was granted temporary mining lease in July, 2013 for mining of material i.e. stone/boulder and murrum from the land in Khasra no. 308/1/1/a, village Amba, Tahsil Sailana, District Ratlam. The question raised by the Applicant was looking to the close proximity to the site of the aforesaid mining lease granted to the Respondent No.1, to the Sailana Wildlife Sanctuary famous for the Lesser Floricon bird, commonly known as Kharmour which is reported to be on the verge of near extinction and the aforesaid Sanctuary is one of the few habitats left over for the breeding purpose preferred by this bird, would be extensively disturbed as a result of the mining activity in such close proximity of the Sanctuary as also the fact, as was revealed before the Tribunal during the hearing, that the extent of the area of the Sailana Wildlife Sanctuary was limited to just about 13 sq.km.

C.R.P. 57/2019 & CM APPL.9037/2019 (for interim relief), CM APPL.9038/2019 (for calling Trial Court record)

1. Petitioner impugns order dated 28.01.2019 whereby the Trial Court has allowed the application under Order 23 Rule 1(1) and 1(3) Code of Civil Procedure (CPC for short) filed by the Respondent and C.R.P. No. 57/2019 Page 1 of 9 permitted the Respondent to withdraw the Suit with liberty to file a fresh Suit for damages.

2. A License Agreement was entered into between the parties on 19.09.2015, whereby Petitioner had agreed to license part of its premises in commercial complex known as "Worldmark 1" located at Asset Area 11, situated at Hospitality District, Indira Gandhi International Airport, New Delhi. The license was entered into for a period of 15 years for the purposes of running of multi-tenanted Food & Beverage concepts under the brand and style of Epicuria.

Lizzo, 31, looked sensational in a sheer dress over a racy corset for her afterparty look, emerging from The Box after a night of party hopping.

Louis Duxbury (pictured outside York Crown Court) was found guilty of inciting religious hatred after the Facebook tirade. He claimed he was exercising his right to free speech.

Iftikhar Gilani's ordeal as an unfairly prosecuted victim of the Official Secrets Act is now behind him, but his record of his experience, published in his book My Days in Prison, reminds us there are many others battling the same harsh treatment under the archaic and oppressive law. Deepa A reports.

The Gujarat state government appears to have very little planned by way of support for the education of Muslim children. What's more the education department appears to be standing in the way of the embattled community's attempts to help itself. Deepa A has more.

Archives, Room Use Only - PN6175.E54 1854

Archives, Room Use Only - TK5743.B45 1920

Archives, Room Use Only - TK5741.T74 1902

Laken Tomlinson and Trent Williams can't spend time together at the 49ers facility, but they are still finding a way to bond.

The 2019 winners of the Art of Building competition, run by the Chartered Institute of Building, have been announced.Take a look at the winners from the competition.

A wall is being constructed in front of a slum along the road connecting Sardar Vallabhbhai Patel International Airport to Indira Bridge.

The two-storey 6,900 square foot structure will be used as an office for general administrative functions by the Dubai Municipality.It was designed in collaboration with Apis Cor, a 3D printing and construction company in Boston.

The hospital, in the commercial hub of Bandra-Kurla Complex, will serve as an isolation facility for non-critical COVID-19 patients.Expected to be ready in a fortnight, the new makeshift facility can be scaled up to 5,000 beds, if needed.The Brihanmumbai Municipal Corporation will run the hospital that will have, among other things, oxygen facilities and pathological laboratories.Sohini Das reports.

Amended building construction bye-laws hailed

September 22, 2015

Coffee and running are addictive in their own unique ways. Each provides a buzz that keeps people coming back for more. In kind, Runkeeper and Starbucks don’t just help people feed their addictions; these apps are as habit-forming as the behaviors they supplement.

Due to its goal-based reward system, Runkeeper’s users don’t feel like their run “counts” unless it’s tracked within the app. And due to Starbucks’ loyalty-based reward system, customers feel compelled to purchase with the app because they don’t want to miss out on the rewards and VIP status that come with being a regular customer.

When apps aren’t addictive, users open them one time, explore for a few minutes, and promptly delete them from their devices. Depending on your industry,...read more
By Bobby Emamian

No-touch systems, infrastructure to work from home are some of the changes

ED attaches part of AJL's Rs 160cr Mumbai building - Times of India

Further details are awaited.

This article presents an overview of the development of two basic software libraries for image manipulation and data visualization in cryo-EM: emcore and emvis.

The data quality requirements for charge density studies on actinide compounds are extreme. Important steps in data collection and reduction required to obtain such data are summarized and evaluated. The steps involved in building an augmented Hansen–Coppens multipole model for an actinide pseudo-atom are provided. The number and choice of radial functions, in particular the definition of the core, valence and pseudo-valence terms are discussed. The conclusions in this paper are based on a re-examination and improvement of a previously reported study on [PPh4][UF6]. Topological analysis of the total electron density shows remarkable agreement between experiment and theory; however, there are significant differences in the Laplacian distribution close to the uranium atoms which may be due to the effective core potential employed for the theoretical calculations.

The performance of automated protein model building usually decreases with resolution, mainly owing to the lower information content of the experimental data. This calls for a more elaborate use of the available structural information about macromolecules. Here, a new method is presented that uses structural homologues to improve the quality of protein models automatically constructed using ARP/wARP. The method uses local structural similarity between deposited models and the model being built, and results in longer main-chain fragments that in turn can be more reliably docked to the protein sequence. The application of the homology-based model extension method to the example of a CFA synthase at 2.7 Å resolution resulted in a more complete model with almost all of the residues correctly built and docked to the sequence. The method was also evaluated on 1493 molecular-replacement solutions at a resolution of 4.0 Å and better that were submitted to the ARP/wARP web service for model building. A significant improvement in the completeness and sequence coverage of the built models has been observed.

Image-processing software has always been an integral part of structure determination by cryogenic electron microscopy (cryo-EM). Recent advances in hardware and software are recognized as one of the key factors in the so-called cryo-EM resolution revolution. Increasing computational power has opened many possibilities to consider more demanding algorithms, which in turn allow more complex biological problems to be tackled. Moreover, data processing has become more accessible to many experimental groups, with computations that used to last for many days at supercomputing facilities now being performed in hours on personal workstations. All of these advances, together with the rapid expansion of the community, continue to pose challenges and new demands on the software-development side. In this article, the development of emcore and emvis, two basic software libraries for image manipulation and data visualization in cryo-EM, is presented. The main goal is to provide basic functionality organized in modular components that other developers can reuse to implement new algorithms or build graphical applications. An additional aim is to showcase the importance of following established practices in software engineering, with the hope that this could be a first step towards a more standardized way of developing and distributing software in the field.

The neutron powder diffractometer POWGEN at the Spallation Neutron Source has recently (2017–2018) undergone an upgrade which resulted in an increased detector complement along with a full overhaul of the structural design of the instrument. The current instrument has a solid angular coverage of 1.2 steradians and maintains the original third-generation concept, providing a single-histogram data set over a wide d-spacing range and high resolution to access large unit cells, detailed structural refinements and in situ/operando measurements.

A new ZnII metallocryptand is presented, with an unprecedented diflexure helix.

Recently, scientists at the Smithsonian Tropical Research Institute in Panama discovered that the brain region responsible for learning and memory is larger in the social queens than in the solitary queens of this species. Their study is the first comparison of the brain sizes of social and non-social individuals of the same species.

The post For sweat bees, being social builds a more developed brain appeared first on Smithsonian Insider.

Researchers from the Smithsonian Conservation Biology Institute, Hawaii Institute of Marine Biology and other partnering organizations spent two weeks at the end of November collecting sperm and embryonic cells during spawning from two species of coral and have built the first frozen repository for the Great Barrier Reef.

The post Smithsonian scientists help build first frozen repository of Great Barrier Reef coral appeared first on Smithsonian Insider.

The National Museum of Natural History will construct a new dinosaur exhibition hall made possible by a $35 million donation from David H. Koch, executive vice president of Koch Industries and philanthropist.

The post $35-million donation will build new dinosaur hall at National Museum of Natural History appeared first on Smithsonian Insider.

NASA’s Interface Region Imaging Spectrograph (IRIS) spacecraft launched at 10:27 p.m. EDT Wednesday, June 26 from Vandenberg Air Force Base, Calif. Its primary goal is […]

The post NASA launches IRIS carrying Smithsonian-built telescope appeared first on Smithsonian Insider.

The black-headed paradise-flycatcher of western and central Africa is a small colorful forest bird that thrives on the flying insects it chases down by swooping, […]

The post These mites should make birds quiver right down to their quills appeared first on Smithsonian Insider.

A word to the wise: don’t ask a paleontologist to pick a favorite fossil. It’s like asking your mother which child she loves most, or […]

The post Fossils help scientists build a picture of the past—and present appeared first on Smithsonian Insider.

Ten years ago, cownose rays in the Atlantic got a bad rap when this species (Rhinoptera bonasus) was accused of excessively eating up scallops in […]

The post Cownose Rays Aquitted: Not Guilty of Decimating Chesapeake Oysters appeared first on Smithsonian Insider.

Smithsonian scientists have joined NASA and other organizations this summer to do something incredible: launch a spacecraft, the Parker Solar Probe, into space and have […]

The post A solar probe is on its way to touch the sun. The Smithsonian built the tool that will measure the sun without melting appeared first on Smithsonian Insider.

Every queen deserves a castle, and the ruler of the Smithsonian’s National Zoo’s naked mole-rat colony is no different. After 27 years in a maze […]

The post Building a naked mole-rat dream home at the Smithsonian’s National Zoo appeared first on Smithsonian Insider.

Left to themselves, coastal wetlands can adapt to sea-level rise. But humans could be sabotaging some of their best defenses, according to a review paper […]

The post Wetlands sinking with human-built structures appeared first on Smithsonian Insider.

How do you bring a nearly complete T. rex back to life? You send the fossils to Canada where craftsmen create a creature of steel. […]

The post First Look: The Smithsonian builds a dinosaur appeared first on Smithsonian Insider.

When it comes time to eat, Abyssinian ground hornbills pick up prey with their beak, toss it into the air and swallow it whole. But […]

The post Building 3D prosthetic beak for Karl, a hornbill appeared first on Smithsonian Insider.

This animation tells a Cheyenne story of how the Big Dipper came to be when a girl and her loyal brothers escape from a bison. […]

The post Quillwork Girl and Her New Seven Brothers appeared first on Smithsonian Insider.

Do you enjoy Tequila? Then you need to raise your glass to the pollinating bats that helped to make it! Here at Smithsonian Science we […]

The post Love tequila? A toast to pollinating bats! appeared first on Smithsonian Insider.

Source: Streetwise Reports   05/06/2020

Testing has been an Achilles heel of the coronavirus pandemic, but ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) has partnered with Dr. Hans Frykman and the BC Neuroimmunology Lab to use its unique technology to create a more accurate antibody test for SARS-CoV-2, the virus that causes Covid-19.

Two main types of tests exist for Covid-19: one that detects the presence of the virus that causes Covid-19, which indicates a person has an active infection, and another that detects antibodies, showing that a person has been exposed to the virus.

The first test that was developed, a test for the presence of the virus, is used mainly to confirm diagnosis of Covid-19 in people who are showing symptoms such as a fever, a dry, persistent cough, difficulty breathing, a sense of restriction in the chest. "They are typical signs of Covid-19, but we would want to know if these are signs of the common flu or a bad cold or Covid-19. We know that Covid can progress really significantly very quickly, especially in individuals with underlying conditions," ProMIS CEO Dr. Elliot Goldstein told Streetwise Reports. "The number of tests is limited, but it's not actually the tests themselves but the reagents and systems you need to run the test that are in short supply."

"Anytime you conduct a test for the virus and get a negative response, the test indicates only that on that day at that time, the person does not have the virus. The person could have had Covid and recovered, or might have had an asymptomatic or very mild case. Or that person could get the virus tomorrow or in three days," Dr. Goldstein explained. "At any point in time the virus test helps indicate the prevalence of the virus—how many people are actually infected—if you test broadly, and at the time you do it, you can determine whether an individual is currently infected or not."

The second type of test, called serological tests or assays, is also known as an antibody test. "When a person is recovering from a viral infection, the immune system makes antibodies—also called immunoglobulins—that are specific to the virus. They neutralize the virus and help clear it out; that's part of the mechanism of why you get better," Dr. Goldstein explained.

One way to see if a person has had Covid is to test for antibodies. "A positive test means you've been exposed to the virus because, in the absence of a vaccine, that's the only way you would have the antibodies. While it's not 100% certain that antibodies neutralize the virus, based on experience with other coronaviruses, it is likely," Dr. Goldstein said. Having the virus neutralized should offer at least some protection against future re-infections.

People who have had positive virus tests know that they have Covid or had Covid and recovered, but many people are asymptomatic or may have had what felt like a light cold, and they want to know if they are at risk, or if they have some protection against the disease. "This is really important for frontline healthcare workers, people working 8-10 hours a day in intensive care or the emergency room with patients known to be very sick with Covid-19; even with protective equipment, they have significant exposure to the virus," Dr. Goldstein explained. "If someone has been through the disease and has natural antibodies, they can't infect someone else. What you want to know on an individual level is am I safe from infection and am I safe for other people."

Generally, antibody testing is a fairly common procedure, Dr. Goldstein explained. When you spin blood in a centrifuge, it separates into three parts: red blood cells, plasma and serum. Serum is where you find antibodies. "ELISA (enzyme-linked immunosorbent assay) is a standard test that looks for antibodies, but it is not specific enough for the Covid-19 virus."

The challenge is there are multiple coronaviruses. "Four different coronaviruses are responsible for the common cold, and then there are others like SARS and MERS. They all have the same sort of halo or corona of protein around the outside of it," Dr. Goldstein said. "They look like the old naval mines used in war. The whole family of coronaviruses look like that. The amino acid sequences of different coronaviruses are not identical but very similar; they share a lot of common structures. There are only really small differences and you can't really pick them up using the usual physical methods."

Studies have shown that up to 90% of individuals in Western countries have been exposed to one or more of the common cold coronaviruses and have antibodies against them. "They look very similar to the coronavirus causing Covid-19. So in Covid-19 antibody tests, the most important thing is it has to be highly specific for the Covid-19 antibodies and doesn't test positive when it identifies a common cold antibody. That is a false positive," said Dr. Goldstein. "It's actually much safer not to have a test that has a lot of false positives because you could base a behavioral decision on faulty information."

Dr. Goldstein cited an example. "If you are testing 1,000 people and there is a 90% prevalence for the cold virus, that means around 900 people have antibodies to the common cold. If the prevalence of the Covid-19 virus is 2%, roughly 20 of the 1,000 would have antibodies to the Covid-19 virus. Let's say the serology test has 95% specificity. That means five times out of 100, it will give a false positive, indicating the presence of Covid-19 antibodies when it is really picking up antibodies against the cold virus. What this means is 5% of 900, or 45 people, will test positive for Covid when they have not had it, and are making decisions based on incorrect information. The consequences of being wrong are dramatic and highlight the need for a very good, high-quality serological test."

How does this relate to Alzheimer's and other neurological diseases that are ProMIS' core competency? "In Alzheimer's, ALS, frontotemporal dementia, Parkinson's disease and other neurological disease, we've been able to use our proprietary, unique technology to identify sites on misfolded proteins that are driving these diseases. Our core technology is the capability to understand what's special about the bad proteins that are causing these diseases and then we can make antibodies highly selective against them. Our technology allows us to identify a region, an epitopes target, which is a series of four to six amino acids where the protein has misfolded. Not only do we know where this target site is located, importantly we also determine the shape (conformation) of this site. Proteins like amyloid and alpha synuclein and TDP 43 misfold and when these proteins misfold they become toxic, they kill neurons, resulting in disease," Dr. Goldstein explained.

ProMIS has transferred that thinking to the virus causing Covid-19. "The corona is composed of the spiky protein. Remember, we want to be able to distinguish between the coronavirus causing the common cold and the coronavirus causing Covid-19," Dr. Goldstein said. "If we can distinguish between the two, we can have an antibody test that's specific for Covid-19. We are looking at a region of the virus called the receptor binding domain, the RBD, that is part of the spike protein and how it attaches to cells. We have a core competency that allows us to identify sites, and not just the location of the sites, but the shape of the sites on complex protein molecules. That allows us then to use that knowledge to create either antibodies or to create serum tests, or even quite frankly, we can use those targets to create vaccines."

Using ProMIS' proprietary technology, the company has been able to "identify a site that we believe is only present on the Covid-19 virus and not on other coronaviruses. We are now initiating the synthesis of several different forms of that site; it's a small area," Dr. Goldstein stated. "That would then transfer to Dr. Hans Frykman's lab at University of British Columbia, a world-class serology lab. Then we will see if the targets we've identified are specific and selective antibodies against Covid-19."

When you test the serum of an individual, if they've been exposed to the virus and have the antibodies, "those antibodies should bind selectively and specifically to the target. So if the antibodies from the patient's serum are binding to the target site, we know it's a Covid-19 virus because that site is only visible in that shape on the Covid-19 virus and not the others. For the validation of our test, only in patients known to have had Covid-19 should we see binding of antibodies against Covid-19 to our target. The second validation is based on testing in serum from subjects known to have never been exposed to Covid-19 virus—such subjects have antibodies only from cold or other coronaviruses, and therefore the antibody test should be negative; there should be no binding. So we should only see binding in serum from a patient known to have recovered from COVID-19, and we should not see binding in serum from an individual known not to have been exposed to COVID-19," Dr. Goldstein explained.

"Our technology basically allows us to zero in with sniper-like precision on the structure of a protein and understand it, not only the structure overall but the shape of the regions on that protein and then that allows us to identify what is specific to that protein, in this case the spiky protein on the virus causing COVID-19," said Dr. Goldstein.

ProMIS expects to have initial results in June.

Disclosure:
1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: PMN:TSX; ARFXF:OTCQB, )